Novotný J, Zvarová M, Prazáková L, Jandlová M, Konvicková L
Oddĕlení klinické hematologie FN U sv. Anny, Brno.
Vnitr Lek. 1995 Oct;41(10):692-5.
Aplastic anaemia (AA) of the chronic type with severe cytopenia is very frequently a difficult therapeutic problem. Patients with granulocyte values below 0.5 G/l are threatened by infections, incl. sepsis possibly with a fatal outcome. If the pool of stem cells for granulocytes is not completely exhausted and can respond to growth factors, these patients can be treated either chronically and/or in risk situations (e.g. injury, surgery) with preparations of the type of a recombinant, granulocyte colony stimulating factor (rhG-CSF), or granulocyte and monocyte colony stimulating factor (rhGM-CSF). The authors present a review of diagnostic and therapeutic algorithms in patients with the AA syndrome and summarize their own experience with the preparation Neupogen Roche (rhG-CSF).
伴有严重血细胞减少的慢性再生障碍性贫血（AA）常常是一个棘手的治疗难题。粒细胞值低于0.5 G/l的患者面临感染威胁，包括可能导致致命后果的败血症。如果粒细胞的干细胞池未完全耗尽且能对生长因子作出反应，这些患者可在慢性期和/或处于危险情况（如受伤、手术）时，使用重组粒细胞集落刺激因子（rhG-CSF）或粒细胞和单核细胞集落刺激因子（rhGM-CSF）制剂进行治疗。作者对AA综合征患者的诊断和治疗算法进行了综述，并总结了他们使用罗式新粒生素（rhG-CSF）制剂的经验。
